Morrow, Linda

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology

Liver Disease Diagnosis and TreatmentDrug Transport and Resistance Mechanisms

Cited by 931

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 293

Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes

Moses, A. C., Young, S. C., Morrow, L. A., O'Brien, M., & Clemmons, D. R. (1996) · Diabetes

Growth Hormone and Insulin-like Growth FactorsDiabetes Treatment and Management

Cited by 291

Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes

Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 170

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects

de la Peña, A., Riddle, M., Morrow, L. A., Jiang, H. H., Linnebjerg, H., Scott, A., Win, K. M., Hompesch, M., Mace, K. F., Jacobson, J. G., et al. (2011) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 125

Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study

Loomba, R., Lawitz, E. J., Frias, J. P., Ortiz-Lasanta, G., Johansson, L., Franey, B. B., Morrow, L., Rosenstock, M., Hartsfield, C. L., Chen, C.-Y., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentFibroblast Growth Factor Research

Cited by 106

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes

Rosenstock, J., Bergenstal, R. M., Blevins, T. C., Morrow, L. A., Prince, M. J., Qu, Y., Sinha, V. P., Howey, D. C., & Jacober, S. J. (2013) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 96

Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans

Baruch, A., Wong, C., Chinn, L. W., Vaze, A., Sonoda, J., Gelzleichter, T., Chen, S., Lewin-Koh, N., Morrow, L., Dheerendra, S., et al. (2020) · Proceedings of the National Academy of Sciences

Fibroblast Growth Factor ResearchAdipokines, Inflammation, and Metabolic Diseases

Cited by 95

Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals

Garito, T., Roubenoff, R., Hompesch, M., Morrow, L., Gomez, K., Rooks, D., Meyers, C., Buchsbaum, M. S., Neelakantham, S., Swan, T., et al. (2018) · Diabetes, Obesity and Metabolism

Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 88

Improved Postprandial Glycemic Control in Patients with Type 2 Diabetes from Subcutaneous Injection of Insulin Lispro with Hyaluronidase

Hompesch, M., Muchmore, D. B., Morrow, L., Ludington, E., & Vaughn, D. E. (2012) · Diabetes Technology & Therapeutics

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 25

Effects of epinephrine on insulin secretion and action in humans: interaction with aging

Morrow, L. A., Morganroth, G. S., Herman, W. H., Bergman, R. N., & Halter, J. B. (1993) · Diabetes

Pancreatic function and diabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 24

Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus

Hompesch, M., Morrow, L., Watkins, E., Roepstorff, C., Thomsen, H. F., & Haahr, H. (2014) · Clinical Therapeutics

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 20